Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10.

[1]  P. Vitti,et al.  Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists. , 2010, Cytokine.

[2]  Hélène Dumortier,et al.  CXCR3, Inflammation, and Autoimmune Diseases , 2009, Annals of the New York Academy of Sciences.

[3]  S. S. Franceschini,et al.  Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. , 2009, The Journal of clinical endocrinology and metabolism.

[4]  W. Scherbaum,et al.  Circulating chemokines in patients with autoimmune thyroid diseases. , 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[5]  A. Lokshin,et al.  Dynamic alteration of soluble serum biomarkers in healthy aging. , 2007, Cytokine.

[6]  G. Mariani,et al.  Iodine-131 Given for Therapeutic Purposes Modulates Differently Interferon-γ-Inducible α-Chemokine CXCL10 Serum Levels in Patients with Active Graves’ Disease or Toxic Nodular Goiter , 2007 .

[7]  M. Rotondi,et al.  Serum levels of the interferon‐γ‐inducible α chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy , 2006 .

[8]  A. Britain,et al.  Synthesis of alpha-chemokines IP-10, I-TAC, and MIG are differentially regulated in human corneal keratocytes. , 2005, Investigative ophthalmology & visual science.

[9]  M. Rotondi,et al.  Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis. , 2005, European journal of endocrinology.

[10]  M. Kimura,et al.  Early chemokine expression induced by interferon-gamma in a murine model of Hashimoto's thyroiditis. , 2004, Experimental and molecular pathology.

[11]  M. Rotondi,et al.  High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. , 2004, The Journal of clinical endocrinology and metabolism.

[12]  P. Libby,et al.  Differential Expression of the IFN-γ-Inducible CXCR3-Binding Chemokines, IFN-Inducible Protein 10, Monokine Induced by IFN, and IFN-Inducible T Cell α Chemoattractant in Human Cardiac Allografts: Association with Cardiac Allograft Vasculopathy and Acute Rejection1 , 2002, The Journal of Immunology.

[13]  G. Stassi,et al.  Autoimmune thyroid disease: new models of cell death in autoimmunity , 2002, Nature Reviews Immunology.

[14]  Su He Wang,et al.  A Unique Combination of Inflammatory Cytokines Enhances Apoptosis of Thyroid Follicular Cells and Transforms Nondestructive to Destructive Thyroiditis in Experimental Autoimmune Thyroiditis1 , 2002, The Journal of Immunology.

[15]  M. Parmentier,et al.  Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. , 2001, Blood.

[16]  H. Ochi,et al.  Lysophosphatidylcholine Inhibits T Cell‐Specific CXC Chemokines IP‐10, MIG, and I‐TAC Expression Induced by IFN‐γ in Human Endothelial Cells , 2001, Annals of the New York Academy of Sciences.

[17]  N. Longo,et al.  Expression of Functional Chemokine Receptors CXCR3 and CXCR4 on Human Melanoma Cells* , 2001, The Journal of Biological Chemistry.

[18]  G. McMahon,et al.  Expression of the Chemokine Receptor CXCR3 and Its Ligand IP-10 During Human Cardiac Allograft Rejection , 2001 .

[19]  A. Luster,et al.  Donor-Derived Ip-10 Initiates Development of Acute Allograft Rejection , 2001, The Journal of experimental medicine.

[20]  M. Baggiolini,et al.  The Ligands of CXC Chemokine Receptor 3, I-TAC, Mig, and IP10, Are Natural Antagonists for CCR3* , 2001, The Journal of Biological Chemistry.

[21]  W. Hancock,et al.  Requirement of the Chemokine Receptor CXCR3 for Acute Allograft Rejection , 2000, The Journal of experimental medicine.

[22]  E. Hudson,et al.  Differential expression and responsiveness of chemokine receptors (CXCR1–3) by human microvascular endothelial cells and umbilical vein endothelial cells , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  H. Malling,et al.  CXC chemokine receptor 3 expression on CD34(+) hematopoietic progenitors from human cord blood induced by granulocyte-macrophage colony-stimulating factor: chemotaxis and adhesion induced by its ligands, interferon gamma-inducible protein 10 and monokine induced by interferon gamma. , 2000, Blood.

[24]  B. Hyman,et al.  Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer’s disease , 2000, Journal of Neuroimmunology.

[25]  Sha Quan,et al.  CXCR3 Expression and Activation of Eosinophils: Role of IFN-γ-Inducible Protein-10 and Monokine Induced by IFN-γ1 , 2000, The Journal of Immunology.

[26]  P. Libby,et al.  Peroxisome Proliferator-Activated Receptor-γ Activators Inhibit IFN-γ-Induced Expression of the T Cell-Active CXC Chemokines IP-10, Mig, and I-TAC in Human Endothelial Cells1 , 2000, The Journal of Immunology.

[27]  Koichi Suzuki,et al.  Hypothyroidism in transgenic mice expressing IFN-γ in the thyroid , 2000 .

[28]  A. Novick,et al.  T cell infiltration into class II MHC-disparate allografts and acute rejection is dependent on the IFN-gamma-induced chemokine Mig. , 1999, Journal of immunology.

[29]  L. Trentin,et al.  The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. , 1999, The Journal of clinical investigation.

[30]  P. Allavena,et al.  Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s , 1998, The Journal of experimental medicine.

[31]  E. Bröcker,et al.  The C–X–C chemokine Mig is highly expressed in the papillae of psoriatic lesions , 1998, The Journal of pathology.

[32]  L. Koniaris,et al.  Human Mig chemokine: biochemical and functional characterization , 1995, The Journal of experimental medicine.

[33]  J. Farber,et al.  5' regulatory region of a novel cytokine gene mediates selective activation by interferon gamma , 1991, The Journal of experimental medicine.

[34]  D. Sansonno,et al.  Endocrine manifestations of hepatitis C virus infection , 2009, Nature Clinical Practice Endocrinology &Metabolism.

[35]  G. Mariani,et al.  Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. , 2007, The Journal of clinical endocrinology and metabolism.

[36]  M. Rotondi,et al.  Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy. , 2006, The British journal of surgery.

[37]  R. Ransohoff,et al.  Chemokine receptor CXCR3: an unexpected enigma. , 2005, Current topics in developmental biology.

[38]  M. Serio,et al.  Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. , 2001, The Journal of clinical investigation.

[39]  D. Patel,et al.  CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. , 2001, Clinical immunology.

[40]  N. Rose,et al.  Hypothyroidism in transgenic mice expressing IFN-gamma in the thyroid. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[41]  H. Malling,et al.  CXCR3 expression and activation of eosinophils: role of IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma. , 2000, Journal of immunology.

[42]  P. Libby,et al.  Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. , 2000, Journal of immunology.